Pharmacoeconomic Analysis of Brigatinib versus Alectinib in First‑Line Treatment of Anaplastic Lymphoma Kinase‑Positive Advanced Non‑Small‑Cell Lung Cancer in China
Brigatinib was a cost-saving (14,203 USD) treatment compared with alectinib in the CMA analysis for the first-line treatment of patients with ALK-positive advanced NSCLC in China.
Authors
- Luis Ortiz-Hernández (ORCID: https://orcid.org/0000-0002-5870-1729)
- Qingqing Chai (ORCID: https://orcid.org/0000-0003-4871-1840)
- Yanjun Zhang (ORCID: https://orcid.org/0000-0002-9702-1128)
- Chunyan Gu (ORCID: https://orcid.org/0000-0002-5303-2060)
Institutions
- Fudan University (CN)
- Huadong Hospital (CN)
- Takeda (United States) (US)
- Takeda (Japan) (JP)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1007/s40487-025-00361-3
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00